Keep up to date with our latest press releases
Aeovian Pharmaceuticals Raises $55 Million to Advance First-in-Class Selective mTORC1 Inhibitor for Tuberous Sclerosis Complex-Related Epilepsy
US FDA approves Otsuka's drug for a type of kidney disease
Domain Therapeutics Appoints Boston-Based Pharma Leader Jean-Marie Cuillerot, M.D., as Chief Medical Officer
Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months
CTI Life Sciences Fund Launches Oligon Therapeutics to Pioneer a New Class of Precision siRNA Therapeutics
Thryv Therapeutics Announces FDA IND Clearance of THRV-1268 for Long QT Syndrome
Glycomine Initiates Dosing in a Global, Randomized, Placebo-Controlled Phase 2b Study of GLM101 for the Treatment of PMM2-CDG
Glycomine Announces $115 Million Series C Financing to Advance Lead Drug Candidate, GLM101, into a Phase 2b Clinical Trial for PMM2-CDG
Find Therapeutics Welcomes Two New Members to Its Board of Directors
Epitopea Announces License and Research Collaboration Agreement with MSD to Identify Cryptigen™ Tumor-Specific Antigens
Epitopea Appoints Klaus Edvardsen M.D., Ph.D. as Chief Medical Officer
Epitopea and Genevant Sciences Announce Collaboration Agreement
Epitopea Closes USD $31 million Pre-Series A Financing
FTX-101 Phase 1 Clinical Trial Launched
Investissement Québec supports Find Therapeutics
IBRILATAZAR (ABTL0812) from AbilityPharma increases chemotherapy effectiveness by 40% in patients with endometrial cancer
FDA clears Find’s IND for Phase 1 study of FTX-101
Epitopea Announces Leadership Transition and New Appointments
enGene Announces Appointment of Ron Cooper as Chief Executive Officer
AstraZeneca Closes Acquisition of Amolyt Pharma
AstraZeneca to buy Amolyt Pharma for $1.05 bln to boost rare-disease portfolio
AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer
Phenomic Enters into Strategic Research Collaboration with Astellas for Solid Tumor Cell Therapies
Phenomic Enters Strategic Collaboration with Boehringer Ingelheim to Discover Novel Targets for Stroma-Rich Cancer Therapies
enGene (Nasdaq: ENGN) Launched as Publicly Traded Genetic Medicines Company
DalCor Pharmaceuticals announces Dal‑GenE‑2 confirmatory trial and closing of Series D financing round
Find Therapeutics Appoints Robert L. Glanzman, M.D., as Chief Medical Officer
Domain Therapeutics announces nomination of best-in-class CCR8 antibody candidate, DT-7012, further strengthening its unique portfolio of GPCR-targeting immunotherapies
Domain Therapeutics announces nomination of best-in-class CCR8 antibody candidate, DT-7012, further strengthening its unique portfolio of GPCR-targeting immunotherapies
enGene, Inc. and Forbion European Acquisition Corp. (“FEAC”, Nasdaq: FRBN) Announce Business Combination Agreement to Create Nasdaq-Listed Biotechnology Company Developing Next-Generation Non-Viral, Locally Administered Gene Therapies
Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group
Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study in patients with advanced, recurrent or metastatic solid tumors: the EPRAD study
Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study
VectivBio Strengthens Business Development Capabilities with Key Appointments
Domain Therapeutics raises $42m Series A financing
Epitopea Announces $14 Million Financing to Advance Cancer Immunotherapeutics
Epitopea Announces $14 Million Financing to Advance Cancer Immunotherapeutics
VectivBio Announces First Patient Dosed in Pivotal Phase 3 Trial of Apraglutide for the Treatment of Short Bowel Syndrome
Pfizer: Doses First Patients as Part of Global Achondroplasia Phase 2 Development Program | MarketScreener
Phenomic AI Launches with $6 Million Financing and an AI/ML Platform for Targeting the Tumor Stroma
Bristol Myers Squibb Receives European Commission Approval for Inrebic® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis
Pfizer Acquires Clinical-Stage Biotech Therachon
Zymeworks Reports IND-Submission Milestone Achieved in Lilly Collaboration
Immunovaccine Inc. Has Applied to List its Common Shares on Nasdaq, Announces Reverse Stock Split
Zymeworks Presents Results of the Completed Dose Escalation Portion of the Ongoing Phase 1 Study of ZW25 at the San Antonio Breast Cancer Symposium
Zymeworks Announces License Agreement with Johnson & Johnson Innovation to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics
PreciThera, Inc. Completes $36 Million Series A Financing
Zymeworks Announces Pricing of Initial Public Offering
Immunovaccine Announces Positive Interim Clinical Data from Ovarian Cancer Study of DPX-Survivac in Combination with Epacadostat
SutroVax Announces Closing of $64M via Series B Financing
CellAegis Devices Announces US$9.5 Million Financing to Support Clinical and Regulatory Advancement of its autoRIC® Device
Profound Medical Corp. Completes Previously Announced $17.4 Million Bought Deal Offering of Common Shares
Toronto’s Xagenic Inc. completes successful beta testing of X1 diagnostic system
Immunovaccine’s Preclinical DPX-NEO Program Demonstrates Positive Anti-Cancer Activity
Venous infers: Early work sufficient to attract $21M for Ilkos’ leg ulcers effort
Immunovaccine Announces Closing of $8 Million Bought Deal Private Placement Financing
Zymeworks Names Diana Hausman, M.D. Chief Medical Officer
Zymeworks and GSK Enter Second Strategic Collaboration to Develop and Commercialize Bi-Specific Antibodies
Xagenic readies X1 molecular diagnostic beta trials
WSJ: Startup Aims to Revive Failed Drug
DalCor raises $100M in series B
With $150M in the bank, Dalcor seeks phase III success with dalcetrapib
Biotech upstart gambles $150M believing it can succeed after Big Pharmas failed on CETP
Zymeworks Completes Acquisition of Kairos Therapeutics Creating a Leader in Biologics Drug Discovery and Development
Zymeworks Announces $61.5 Million Financing to Support the Clinical Development of its Pipeline of Azymetric™ Antibody Therapeutics
Investissement Québec investit 10 millions de dollars dans le fonds CTI Sciences de la Vie II
PHEMI Closes $12.2 Million Venture Financing
SutroVax raises $22 million in Series A
XTuit Pharmaceuticals Closes $22 Million Series A Financing to Advance Novel Microenvironmental Modulators for Cancers and Fibrotic Disorders
Impressive Industry Leaders Elected to BIOTECanada Board of Directors
NEOMED Announces Appointment of Dr. Laurence Rulleau to Its Board of Directors
NEOMED Announces Appointment of Dr. Laurence Rulleau to Its Board of Directors
CTI Life Sciences successfully raises new C$ 134 Million venture capital fund
Xagenic Announces Second Closing of $25.5M Series B Financing
Medicago announces agreement to be acquired by Mitsubishi Tanabe Pharma in a transaction valued at $357M
Fonds de solidarité FTQ, CTI Life Sciences Fund and Ferring Pharmaceuticals Create a New Biotech in Québec
Closing of acquisition of Enobia by Alexion – Yet another successful portfolio exit for CTI’s Life Sciences Fund
Xagenic Inc. Closes C$10 Million Series A Financing
Alexion to Acquire Enobia Pharma Corp. and First Potential Treatment for Patients with Hypophosphatasia (HPP)
Medicago Completes $25 Million Private Placement
Zymeworks Snags $187M Deal With Merck to Discover Multi-Pronged Antibodies
Enobia Pharma Raises US $40 million
Medicago Announces Closing of C$17.4 Million Equity Offering
Sanofi-Aventis to acquire TargeGen Inc., a US biopharmaceutical company
Zymeworks Closes C$3.2M Round of Financing
Somnus Therapeutics Closes US$15 Million Series A Financing with CTI Life Sciences and Care Capital
NeurAxon Announces Closing of Convertible Debenture Financing
Enobia Pharma Inc. Raises US$50M from Current Investors in Series C Financing
Zymeworks Closes C$3.4M Financing Round and Announces Changes to its Board of Directors
Enobia Pharma Inc. Closes C$40.1 million Series B Financing Round
Chlorion Pharma Inc. Closes C$6.0 million Financing Round
TargeGen Inc. Closes $40.0M Series D Financing Round
CTI Life Sciences Fund Will Invest $100 Million in Business Seeds and Start-ups
